Abstracts tagged "infliximab"

Abstract Number: 042 • 2020 Pediatric Rheumatology Symposium
Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions
Mary Culp ¹, Dusty Lewis ¹, Bethanne Thomas ², Fatima Barbar-Smiley ³, Kyla Driest ⁴, Edward Oberle ⁴, Stacy Ardoin ¹ and Kelly Wise¹, ¹Nationwide Children's Hospital, Columbus, ²Nationwide Children's, Columbus, ³Nationwide Children's Hospital, Columbus, Ohio, ⁴Division of Rheumatology, Nationwide Children's Hospital, Columbus
Background/Purpose: Infliximab is an effective treatment for many pediatric rheumatic conditions, but high medication cost creates a barrier to patient access. Biosimilar drugs are proven…
Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…
Abstract Number: 48 • 2019 ACR/ARP Annual Meeting
Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Maria Luque-Tevar ¹, Patricia Ruiz-Limon ³, Laura Pérez-Sanchez ⁴, Sara Remuzgo-Martínez ⁵, Alejandro Ibañez-Costa ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁶, Maria del Carmen Abalos-Aguilera ¹, Andres Delgado-Campos ⁷, Rafaela Ortega ¹, Raquel López-Mejías ⁵, M Angeles Aguirre ⁸, Alejandro Escudero ⁷, Eduardo Collantes-Estevez ⁶, Miguel A. González-Gay ⁹ and Carlos Perez-Sanchez ¹⁰, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain, Málaga, Spain, ⁴MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain, ⁹Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain, ¹⁰Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: 1. To identify and characterize specific immunological, inflammatory and epigenetic determinants involved in the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients. 2.…
Abstract Number: 202 • 2019 ACR/ARP Annual Meeting
Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian P. Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Biosimilar use in North America is relatively low, and real-world comparisons of biosimilars and their originator biologics are lacking. We assessed risk factors associated…
Abstract Number: 519 • 2019 ACR/ARP Annual Meeting
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha. Following demonstration…
Abstract Number: 520 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have…
Abstract Number: 536 • 2019 ACR/ARP Annual Meeting
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis
Bruno Fautrel¹, Yoram Bouhnik ², Guillaume Desjeux ³, Ulrich Freudensprung ⁴, Janet Addison ⁵ and Amira Brigui ⁶, ¹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ²Beaujon Hospital, Department of Gastroenterology, AP-HP, Paris Diderot University, Clichy, France, ³E-health Services Sanoïa, Digital CRO, Gémenos, France, ⁴Biogen International GmbH, Zug, Switzerland, ⁵Biogen UK, Maidenhead, United Kingdom, ⁶Biogen France SAS, Paris, France
Background/Purpose: SB2 is approved in the EU as an infliximab (IFX) biosimilar, having demonstrated bioequivalence and similar efficacy, safety and immunogenicity as the reference. There…
Abstract Number: 1115 • 2019 ACR/ARP Annual Meeting
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Bruno Emond ¹, Kay Sadik ², Marie-Hélène Lafeuille ¹, Willy Wynant ¹, Aurélie Côté-Sergent ¹, Patrick Lefebvre ¹, Kimberly Woodruff ² and Timothy Fitzgerald³, ¹Analysis Group, Inc, Montreal, QC, Canada, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis…
Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Najima Mwase ¹, Theresa Hennard ², Joseph McDonald ³, Amy Cassedy ⁴, Onengiya Harry ³ and Sheila Angeles-Han⁵, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka¹, Koji Oba^2,3, Takao Koike^4,5, Nobuyuki Miyasaka⁶, Tsuneyo Mimori⁷, Tsutomu Takeuchi⁸, Shintaro Hirata⁹, Eiichi Tanaka¹⁰, Hidekata Yasuoka¹¹, Yuko Kaneko⁸, Kosaku Murakami⁷, Tomohiro Koga¹², Kazuhisa Nakano¹³, Koichi Amano¹⁴, Kazuyasu Ushio¹⁵, Tatsuya Atsumi¹⁶, Masayuki Inoo¹⁷, Kazuhiro Hatta¹⁸, Shinichi Mizuki¹⁹, Shohei Nagaoka²⁰, Shinichiro Tsunoda²¹, Hiroaki Dobashi²², Nao Horie³ and Norihiro Sato³, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁵NTT Sapporo Medical Center, Sapporo, Japan, ⁶Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ¹²Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹⁵Ushio Clinic, Osaka, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷Utazu hospital, Utatsu-cho, Japan, ¹⁸Department of General Medicine, Tenri Hospital, Tenri, Japan, ¹⁹Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²¹Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²²Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan
Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 602 • 2018 ACR/ARHP Annual Meeting
Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
Silje Watterdal Syversen¹, Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Johanna Gehin³, Cato Mork⁴, Tore Kvien⁵, Jorgen Jahnsen⁶, Nils Bolstad³ and Espen A. Haavardsholm⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴None, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
Background/Purpose: The purpose is to develop an individualised treatment strategy based on Therapeutic drug monitoring (TDM) in order to optimise efficacy of Infliximab (INX) treatment.…
Abstract Number: 615 • 2018 ACR/ARHP Annual Meeting
The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
Mayumi Matsuda¹, Yu Funakubo Asanuma², Yoshinobu Nakao³, Hiroaki Yazawa², Takuma Tsuzuki Wada⁴, Noritsune Kouzu⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology, Saga University Hospital, Saga, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ⁵Saitama Medical University, Moroyama, Japan
Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing…
Abstract Number: 977 • 2018 ACR/ARHP Annual Meeting
Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Andrew Fell¹, Emma Carson¹, Gillian Coyle¹, Neil Martin¹, Jo Walsh¹ and Janet Gardner-Medwin², ¹Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, ²School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system…

1
2
3
…
6
Next Page »